Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Discovery

• Publication date

  2011-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8274.CD-11-0048PMID 22586318
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes

  2022cited by this paper
• Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

  2012cited by this paper
• Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

  2011cited by this paper
• Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

  2011cited by this paper
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

  2011cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.

  2010cited by this paper
• 362 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers

  2010cited by this paper
• PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2007cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Breast and ovarian cancer.

  2003cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper

• Therapeutic implications of antiangiogenic agents and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors in breast cancer: Current status and future perspectives

  2025cites this paper
• Triterpenoids Isolated from Cassia fistula can be a Potent Anti-Tumor Agent: A Review

  2024cites this paper
• Molecular pathways and therapeutic strategies in dermatofibrosarcoma protuberans (DFSP): unravelling the tumor’s genetic landscape

  2024cites this paper
• DTX3L E3 ligase targets p53 for degradation at poly ADP-ribose polymerase-associated DNA damage sites.

  2023cites this paper
• DNA repair pathways in breast cancer: from mechanisms to clinical applications

  2023cites this paper
• Counting the cost of public and philanthropic R&D funding: the case of olaparib

  2022cites this paper
• New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.

  2021cites this paper
• Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future

  2020cites this paper
• Young Age and Breast Cancer Biology

  2020cites this paper
• Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options.

  2020cites this paper
• A decade of clinical development of PARP inhibitors in perspective

  2019cites this paper
• Effect of younger age on survival outcomes in T1N0M0 breast cancer: A propensity score matching analysis

  2019cites this paper
• Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer

  2018cites this paper
• Genetic dissection of the BRCA2 promoter and transcriptional impact of DNA variants

  2018cites this paper
• Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

  2018cites this paper
• Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage

  2018cites this paper
• Curcumin sensitizes lymphoma cells to DNA damage agents through regulating Rad51-dependent homologous recombination.

  2018cites this paper
• Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18

  2017cites this paper
• Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry

  2016cites this paper
• Innovative Exploratory Clinical Approaches for Relapsed and / or Refractory Metastatic Ewing ’ s Sarcoma

  2016cites this paper
• Heritable Gastrointestinal Cancer Syndromes.

  2016cites this paper
• Synthetic lethality: the road to novel therapies for breast cancer.

  2016cites this paper
• Disparities in Cancer Genetic Risk Assessment and Testing.

  2016cites this paper
• Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.

  2016cites this paper
• Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma

  2015cites this paper
• Chapter 19 – Cancer

  2015cites this paper
• CNS Metastasis Patterns in BRCA1/2 Mutation Associated and Non-BRCA Associated Breast Cancers

  2015cites this paper
• PARP inhibitors in the management of breast cancer: current data and future prospects

  2015cites this paper
• Updates on the management of breast cancer brain metastases.

  2014cites this paper
• Biology of breast cancer in young women

  2014cites this paper
• Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status

  2014cites this paper
• Inhibited effects of veliparib combined doxorubicin for BEL-7404 proliferation of human liver cancer cell line.

  2014cites this paper
• Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy.

  2014cites this paper
• Application of the concept synthetic lethality toward anticancer therapy: a promise fulfilled?

  2014cites this paper
• Cancer genomics and inherited risk.

  2014cites this paper
• , RNF 8 Repair Independent of ATM , MDC 1 , and Ubiquitylation , and Double-Strand DNA Poly ( ADP-Ribose ) Activation , BAL 1 and Its Partner E 3 Ligase , BBAP , Link

  2013cites this paper
• Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer

  2013cites this paper
• BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

  2013cites this paper
• Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors.

  2013cites this paper
• The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells

  2013cites this paper
• ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition

  2013cites this paper
• From polypharmacology to target specificity: the case of PARP inhibitors.

  2013cites this paper
• Mechanisms of resistance to therapies targeting BRCA-mutant cancers

  2013cites this paper
• MCPH1 Protein Expression in Normal and Neoplastic Lung Tissues.

  2013cites this paper
• Synthetic lethality and functional study of DNA repair defects in ERCC1-deficient non-small-cell lung cancer

  2013cites this paper
• The promise of combining inhibition of PI3K and PARP as cancer therapy.

  2012cites this paper
• PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.

  2012cites this paper
• Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.

  2012cites this paper
• The DNA damage response and cancer therapy

  2012cites this paper
• BAL1 and Its Partner E3 Ligase, BBAP, Link Poly(ADP-Ribose) Activation, Ubiquitylation, and Double-Strand DNA Repair Independent of ATM, MDC1, and RNF8

  2012cites this paper
• The BRCA1 Breast Cancer Suppressor: Regulation of Transport, Dynamics, and Function at Multiple Subcellular Locations

  2012cites this paper
• The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions

  2011cites this paper
• Cancer Management and Research Dovepress Dna Repair in Cancer: Emerging Targets for Personalized Therapy

  year unknowncites this paper